Pfizer (PFE) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Pfizer (PFE) over the past year, gaining 52.2% versus a gain of 9.4%. Over five years, TAK leads with a +60.9% price change compared with -49.3% for PFE. Pfizer is the larger company by market cap ($156.18 billion vs $69.55 billion), about 2.2 times the size.
On valuation, Pfizer trades at a lower forward P/E (9.3x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 7.85%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PFE | TAK |
|---|---|---|
| Share price | $27.40 | $21.77 |
| Market cap | $156.18B | $69.55B |
| 1-day change | -0.51% | +1.68% |
| YTD return | +10.04% | +39.64% |
| 1-year return | +9.42% | +52.24% |
| 5-year return | -49.26% | +60.90% |
| P/E ratio (TTM) | 39.14 | 311.00 |
| Forward P/E | 9.28 | 41.08 |
| EPS (TTM) | $0.70 | $0.07 |
| Dividend yield | 7.85% | 927.88% |
| Annual dividend | $2.15 | $202.00 |
| Revenue (latest FY) | $62.58B | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $7.77B | — |
| Gross margin | 74.33% | — |
| Net margin | 12.42% | — |
| 52-week high | $31.44 | $22.07 |
| 52-week low | $23.62 | $14.16 |
| Distance from 52-week high | -12.85% | -1.36% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +10.29% | +12.68% |
| Average volume | 33.52M | 2.73M |
| Shares outstanding | 5.70B | 3.19B |
| Employees | 75,000 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pfizer is about 2.2 times larger than Takeda Pharmaceutical by market value ($156.18B vs $69.55B).
- TAK has outperformed PFE by 42.8 percentage points over the past year.
- Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 39.1x trailing P/E).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 7.85%).
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
PFE vs TAK FAQ
Which is bigger, Pfizer or Takeda Pharmaceutical?
Pfizer (PFE) is larger, with a market capitalization of $156.18B compared with $69.55B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, PFE or TAK?
TAK returned +52.24% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PFE or TAK?
PFE has the lower trailing P/E at 39.1, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Pfizer or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 927.88%, compared with 7.85% for Pfizer.
Are Pfizer and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.